Chagas Disease Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Chagas Disease Treatment Market Trends and Insights

Migrant Screening Mandates Create High-Conversion Treatment Demand in Non-Endemic Markets

In July 2025, Washington State issued a provider alert recommending Chagas screening for patients who had lived in Mexico, Central America, or South America for 6 months or longer. The alert expanded institutional screening protocols used at Boston Medical Center and NYC Health + Hospitals.^{[1]World Health Organization, “Chagas Disease (American Trypanosomiasis),” World Health Organization, who.int} A 2026 study reported 7.8% seroprevalence among screened migrants in Barcelona, including 12.9% among Bolivian nationals. Specialist settings in non-endemic countries initiated treatment for 80% to 85% of confirmed diagnoses, compared with less than 30% in parts of Latin America, strengthening the Chagas disease treatment market through faster specialist care and reimbursement access.^{[2]Washington State Department of Health, “Provider Alert, Low Screening Coverage for Chagas Disease in Washington,” Washington State Department of Health, doh.wa.gov}

Congenital Test-And-Treat Programs Accelerate Pediatric Formulation Demand

Congenital transmission remained a leading route for new Chagas infections in non-endemic countries. Treatment during the first year of life achieved cure rates above 90%, compared with 10% to 20% in the chronic phase. PAHO’s 2025 program framework set a 95% etiological treatment target for children under 14 who tested positive for T. cruzi, as well as pregnant women and newborns under its EMTCT Plus approach.^{[3]O. Bernal et al., “Towards Effective Coverage of Chagas Disease, A Community-Based Approach in Migrant Populations,” International Journal for Equity in Health, link.springer.com} The 12.5 mg pediatric benznidazole tablet developed by DNDi, Laboratorio ELEA Phoenix, and Mundo Sano Foundation improved dosing precision, while DNDi’s collaboration with CONICET evaluated MultiCruzi-measured antibody decline in children as a surrogate regulatory endpoint.

WHO And PAHO Programs Sustain Volume While Setting Endemic-Market Pricing Ceilings

Multilateral procurement served as both a demand base and pricing constraint for the Chagas disease treatment market. In January 2025, PAHO distributed more than 1.3 million nifurtimox tablets to 19 endemic countries, enabling more than 4,500 complete treatments. In November 2025, WHO and Bayer renewed their 2025-2030 collaboration, committing USD 15.5 million in donated medicines and USD 9.45 million in program support. These programs supported treatment data and continuity while limiting commercial pricing in public procurement settings.

Pediatric Drug Registrations Unlock Commercial Formulary Access in High-Value Markets

In October 2025, Spain authorized nifurtimox reimbursement under its National Health System, marking the first formal listing of a Chagas medicine in a European national formulary and replacing the foreign-drug exemption route. The decision provided a reference point for Italy, France, and Germany as they considered similar access pathways. The FDA established a pediatric regulatory precedent for benznidazole through its approval pathway. These developments created a clearer route to pediatric formulary inclusion when approvals aligned with practical formulations and screening programs.

Asymptomatic Presentation Suppresses Diagnosis-To-Treatment Conversion Rates

Only 10% of people living with Chagas disease had received a diagnosis, and 1% had received timely treatment, limiting the addressable patient pool. Up to 70% of chronic patients remained asymptomatic for years or decades. A 2026 DNDi-supported field study in Santiago del Estero, Argentina, identified fewer than 50 infections among 1,380 people screened through active community rapid testing, despite trained staff. Guatemala clinic records covering 590 patients showed that 77.5% initiated therapy, highlighting the need for health-system investment to improve diagnosis-to-care conversion.

Adverse-Event Burden Drives Discontinuation And Limits Effective Utilization

A 2025 Boston Medical Center analysis found that 84.3% of patients who started benznidazole experienced at least one adverse event. Allergic, gastrointestinal, and neuropsychiatric reactions affected 47.0%, 45.8%, and 39.8% of patients, respectively, while rash led to discontinuation in 22.9% of cases. Guatemala clinic records showed a 71.5% adverse-reaction rate and multisystem reactions in 59% of cases. The NuestroBen Phase III trial enrolled 540 participants in Argentina and Bolivia to compare two- and four-week benznidazole regimens with the standard eight-week course, with results expected by late 2028.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Benznidazole Leads While Nifurtimox Gains Regulatory Support

Benznidazole held 68.40% of product-type revenue in 2025, supported by its WHO first-line designation, pediatric approval, and manufacturing base in Argentina and Brazil. It accounted for the largest share of the Chagas disease treatment market within the product category. Price differences between North American and European pharmacies and PAHO-supported supply in endemic countries limited revenue capture. Its US orphan-drug exclusivity expired in August 2024, although limited manufacturer interest has constrained generic competition.

Nifurtimox is forecast to expand at a CAGR of 10.23% through 2031, the fastest rate in this product category. Spain added the product to its formulary in October 2025, broadening patient access, while Bayer’s 30 mg disintegrating pediatric tablet supports treatment for younger patients. WHO and PAHO access programs continue to sustain availability in endemic countries. Growth depends on screening, reimbursement, and providers’ ability to manage treatment tolerability.

By Treatment Type: Antiparasitic Protocols Lead While Organ-Specific Care Broadens Demand

Etiological antiparasitic treatment accounted for 61.45% of treatment-type revenue in 2025. The segment led revenue because parasite elimination remains the clinical priority in acute and pediatric cases, with cure rates approaching or exceeding 90% when treatment begins early. Medicines targeting T. cruzi directly remain central to clinical care and public procurement. Public programs also prioritize treatment for diagnosed children and newborns.

Symptomatic and organ-specific treatment is forecast to grow at a CAGR of 9.80% through 2031. Growth is supported by cardiomyopathy and gastrointestinal complications affecting 20% to 30% of chronic patients. In April 2026, Brazil’s Ministry of Health and Fiocruz launched Phase 2 of a selenium trial for chronic chagasic cardiomyopathy, committing BRL 8.6 million, equivalent to USD 1.6 million. Dedicated cardiac therapies could broaden the revenue base, while long-term follow-up supports demand among patients with chronic complications.

By Disease Phase and Clinical Form: Chronic Disease Anchors Revenue While Acute Detection Rises

Chronic Chagas disease accounted for 65.77% of disease-phase revenue in 2025, supported by a large patient reservoir. Many patients are identified through migrant screening rather than symptom-driven diagnosis. The NuestroBen Phase III trial is evaluating shorter benznidazole regimens for chronic indeterminate patients across eight sites in Argentina and Bolivia, with results expected by the end of 2028. Earlier diagnosis and improved treatment completion remain key market requirements.

Acute Chagas disease is forecast to grow at a CAGR of 9.45% through 2031. Brazil recorded 627 acute cases in preliminary 2025 data, with 97% reported in the North and largely linked to foodborne transmission, according to the supplied research. WHO and PAHO congenital elimination goals classify congenital infections as acute disease, creating demand for prompt treatment. Decentralized testing and improved point-of-care diagnostics can strengthen early diagnosis, referral, and pediatric treatment demand.

By Dosage Form: Tablets Dominate While Injectables Serve Acute-Care Settings

Tablets held 75.6% of dosage-form revenue in 2025. Oral medicines remain the standard of care for established Chagas disease therapies and support outpatient treatment courses lasting 60 to 90 days. Their ease of administration supports delivery beyond tertiary hospitals, although adverse-event monitoring remains necessary. Pediatric tablet options also improve dose management for younger patients.

Injectables are forecast to grow at a CAGR of 10.56% through 2031, the highest rate in the dosage-form category. Growth reflects hospital-based treatment for severe acute, congenital, and immunosuppression-reactivated infections. A 2025 scientific study developed lipid-based self-emulsifying nifurtimox systems and poly(ε-caprolactone) implants with enhanced anti-T. cruzi activity in animal models. Suspension and experimental nanocapsule formats remain in early development and are not expected to materially affect revenue before 2028.

By End User: Hospitals Lead While Specialty Clinics Expand

Hospitals held 57.66% of end-user revenue in 2025. They led the segment by managing severe acute cases, cardiac complications, and supervised treatment initiation. Hospitals also provide specialist support for adverse-event management, complex disease, and reactivated infections. Public referral systems frequently direct patients to hospitals following a positive test, reinforcing their role in diagnosis, treatment initiation, and clinical monitoring.

Specialty infectious disease clinics are forecast to grow at a CAGR of 8.88% through 2031. Boston Medical Center’s Strong Hearts program screened 14,354 patients through 2023 and reported a 0.7% prevalence rate, according to the supplied research. Similar care models are being replicated at NYC Health + Hospitals Bellevue and Metropolitan campuses. The Novartis-supported Sertão do Pajeú project in Pernambuco and DNDi programs in Colombia, Guatemala, and Bolivia are assessing local treatment delivery and community health worker models.

Geography Analysis

North America held 39.44% of the Chagas disease treatment market share in 2025, making it the largest regional contributor. The United States supported this position through FDA-approved medicines, specialist infectious disease networks, and private insurance reimbursement. An estimated 300,000 people with T. cruzi infection live in the United States. CDC training and state provider alerts improved physician awareness, while higher diagnosis-to-treatment conversion supported commercial medicine use. Canada benefited from growing Latin American immigration, while Mexico contributed to the endemic demand, partly served through PAHO procurement.

South America carried the largest endemic patient burden, but donation and public procurement programs limited its commercial revenue share. Brazil remained the largest treatment setting by patient volume, reporting 8,106 chronic cases in preliminary 2025 data, concentrated in Minas Gerais, Bahia, and Goiás. In April 2026, Brazil committed BRL 12 million, equivalent to USD 2.2 million, for surveillance and vector control in 155 priority municipalities across 17 states. Argentina produced benznidazole, the active pharmaceutical ingredient, and the 12.5 mg pediatric tablet, while Laboratorio ELEA Phoenix co-sponsored the NuestroBen Phase III trial. In 2025, Colombia adopted rapid diagnostic tests into its official Chagas algorithm, potentially expanding detection from hospitals to community settings.

Asia-Pacific is projected to grow at an 11.88% CAGR through 2031, representing the fastest regional growth rate in the Chagas disease treatment market. Japan and Australia improved detection among Latin American migrants through tertiary infectious disease departments, while commercial distribution generated higher revenue per treated patient than donation-based supply. Europe also expanded, as Spain’s October 2025 formulary decision provided a reference for other countries, and the Italian screening analysis supported national programs. The Middle East and Africa remained at an early awareness stage, with cases primarily linked to Latin American labor migrants in Gulf Cooperation Council countries.